Development and Validation of a Triplex RT-qPCR Assay for Rapid Clinical Diagnosis and Serotyping of Feline Infectious Peritonitis Virus
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27052204 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Ruilong Xiao und 10 weiteren Autor:innen. Beteiligte Einrichtung: College of Veterinary Medicine, Beijing University of Agriculture, Beijing 102206, China. Hauptthemen laut MEDLINE: Coronavirus, Feline, Feline Infectious Peritonitis, Serotyping, Multiplex Polymerase Chain Reaction. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Key Research and Development Program of China, National Key Research and Development Program of China.
Abstract (Originalsprache)
Feline infectious peritonitis (FIP) is a highly lethal disease caused by feline infectious peritonitis virus (FIPV), which poses significant diagnostic challenges in clinical practice. FIPV is divided into two serotypes (serotype I and serotype II) based on distinct serological responses driven by substantial sequence divergence in the spike (S) protein. Serotype I predominates in Europe and North America, whereas serotype II is more common in Asia. In this study, we developed a triplex reverse transcription quantitative PCR (RT-qPCR) assay for simultaneous detection and serotyping of FIPV. Primers and TaqMan probes were designed to target the conserved nucleocapsid (N) gene and serotype-specific regions within the S gene. After systematic optimization of reaction conditions, the final assay employed an annealing temperature of 64 °C and optimized primer–probe concentrations. The assay exhibited excellent linearity (R2 > 0.99 for all targets), with amplification efficiencies ranging from 97.39% to 109.97%. No cross-reactivity was observed with other common feline pathogens, confirming high specificity. The limit of detection was as low as 0.5 copies/µL, and intra-assay repeatability showed coefficients of variation below 2.1%. Clinical validation using 63 feline samples revealed an overall FIPV positivity rate of 21.63%, with serotype II (17.46%) markedly more prevalent than serotype I (3.17%). Collectively, this triplex RT-qPCR assay demonstrates high sensitivity, exceptional specificity, and robust reproducibility, making it a valuable tool for rapid clinical diagnosis through the simultaneous detection of feline coronavirus (FCoV) and serotyping of FIPV.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Veterinary Medicine, Beijing University of Agriculture, Beijing 102206, China.
- Institute of Animal Sciences, Chinese Academy of Agricultural Sciences, Beijing 100193, China.
ORCID-Profile: Ying Huang, Weifeng Yuan
Förderung
- the National Key Research and Development Program of China
- National Key Research and Development Program of China
Zitieren
APA
Xiao, R., Chen, Y., Huang, Y., Tao, C., Jin, X., Gu, Y., Yuan, W., Song, W., Wang, Z., Li, H., & Jia, H. (2026). Development and Validation of a Triplex RT-qPCR Assay for Rapid Clinical Diagnosis and Serotyping of Feline Infectious Peritonitis Virus. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27052204
Vancouver
Xiao R, Chen Y, Huang Y, Tao C, Jin X, Gu Y, et al. Development and Validation of a Triplex RT-qPCR Assay for Rapid Clinical Diagnosis and Serotyping of Feline Infectious Peritonitis Virus. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27052204
BibTeX
@article{Xiao2026,
author = {Xiao, Ruilong and Chen, Yanhe and Huang, Ying and Tao, Chunhao and Jin, Xinxin and Gu, Yingjia and Yuan, Weifeng and Song, Wenjin and Wang, Zhen and Li, Huanrong and Jia, Hong},
title = {Development and Validation of a Triplex RT-qPCR Assay for Rapid Clinical Diagnosis and Serotyping of Feline Infectious Peritonitis Virus},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27052204}
}
EUVIMED